Esmolol Hydrochloride and Stamaril

• Generic Name: esmolol
• Dosage Forms: n.a.
• Other Brand Names: Brevibloc

Rapid, temporary control of ventricular rate in patients with supraventricular tachycardia (SVT) (e.g., atrial flutter and/or fibrillation, sinus tachycardia, junctional tachycardia, atrial tachycardia).

Vagal maneuvers and/or IV adenosine are considered first-line interventions for acute treatment of SVT when clinically indicated; if such measures are ineffective or not feasible, may consider an IV β-adrenergic blocking agent. Although evidence of efficacy is limited, experts state that overall safety of β-blockers warrants use.

May be used in patients with nonpreexcited atrial flutter and/or fibrillation to control rapid heart rate associated with surgical or other manipulative procedures (e.g., cardiac catheterization), or other emergent situations requiring short-term control of ventricular rate.

May be useful in patients with noncompensatory sinus tachycardia for short-term control of rapid heart rate requiring intervention.

Not intended for chronic use when other more appropriate antiarrhythmic agents would be preferred.

Treatment of intraoperative and postoperative hypertension and/or tachycardia. Has been used effectively for prevention or treatment of increases in BP associated with surgical events. However, use for prevention of such events is not recommended by the manufacturer.

Management of hypertensive emergencies in adults.

Rapid reduction of BP in the management of acute severe hypertension in pediatric patients with life-threatening symptoms.

Treatment to produce controlled hypotension during anesthesia in order to reduce bleeding resulting from surgical procedures (e.g., orthopedic surgery, neurosurgery).

Has been used for the management of acute tachyarrhythmias complicating acute MI and to minimize myocardial ischemia following acute MI or associated with unstable angina.

While current expert guidelines recommend an oral β-blocker in all patients with MI who do not have manifestations of heart failure, evidence of low-output state, increased risk of cardiogenic shock, or any other contraindications to β-blocker therapy, use of IV β-blockers should be limited to patients with refractory hypertension or ongoing ischemia.

• Generic Name: yellow fever vaccine
• Dosage Forms: n.a.
• Other Brand Names: Stamaril, YF-Vax

Yellow fever is a serious disease caused by a virus that is spread through the bite of an infected mosquito. Yellow fever can cause fever and flu-like illness, jaundice (yellowing of the eyes and skin), liver failure, lung failure, kidney failure, vomiting of blood, and possibly death.

Stamaril is recommended for people who plan to live in or travel to areas where yellow fever is known to exist, or those who are otherwise at high risk of coming into contact with the virus.

This vaccine is used to help prevent yellow fever in adults and children who are at least 9 months old. The vaccine works by exposing you to a small dose of the virus, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

You should receive the vaccine at least 10 days prior to your arrival in an area where you may be exposed to the virus.

This vaccine is also recommended for people who work in a research laboratory and may be exposed to yellow fever virus through needle-stick accidents or inhalation of viral droplets in the air.

Like any vaccine, the Stamaril may not provide protection from disease in every person.